awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q55002072-27E0D717-9B83-42FF-84B9-F9793018255B
Q55002072-27E0D717-9B83-42FF-84B9-F9793018255B
BestRank
Statement
http://www.wikidata.org/entity/statement/Q55002072-27E0D717-9B83-42FF-84B9-F9793018255B
Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma.
P2860
Q55002072-27E0D717-9B83-42FF-84B9-F9793018255B
BestRank
Statement
http://www.wikidata.org/entity/statement/Q55002072-27E0D717-9B83-42FF-84B9-F9793018255B
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
5b0c77d2edbe925f93f7832b052af4b569806128
P2860
NCIC CTG IND.190 phase I trial of dalotuzumab (MK-0646) in combination with cisplatin and etoposide in extensive-stage small-cell lung cancer.